Ultragenyx Pharmaceutical Inc Ultragenyx DTX401 Phase 1/2 Cohort 2 Data Conference Call Transcript
Good day, ladies and gentlemen.
Welcome to the Ultragenyx DTX401 Data Conference Call.
(Operator Instructions)
I would now like to turn the call over to Ms. Danielle Keatley, Senior Director of Investor Relations. Ma'am, you may begin.
Thank you.
Good morning and welcome to the Ultragenyx Conference Call to discuss the interim results of the Phase I/II study of DTX401, our gene therapy for the treatment of GSDIa. These results were presented at the SSIEM Annual Symposium earlier today, and we issued a press release detailing the data results. Both the press release and the SSIEM presentation can be found on our website at ultragenyx.com.
With me today are Emil Kakkis, Chief Executive Officer and President of Ultragenyx; and Dr. David Weinstein, Professor and Director, Glycogen Storage Disease Program at Connecticut Children's Medical Center and UConn Health.
I would like to remind investors that this
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |